

FOR IMMEDIATE RELEASE

Brisbane, Australia 30th January 2024

Australian Natural Therapeutics Group (ANTG) announces major expansion in Brisbane, bolstering Australia's Medicinal Cannabis Market

Australian Natural Therapeutics Group (ANTG), a leading supplier of scientifically proven, safe, and effective plant-based medicines has announced a significant expansion of its cultivation and manufacturing facilities in Brisbane, following Office of Drug Control (ODC) approval permits.

After a rigorous 11-month process, ANTG has been granted permits for cultivation and manufacturing, enabling the company to increase its production capabilities and elevate the Australian medicinal cannabis industry, by providing:

Increased Biomass Cultivation: The permits allow ANTG to cultivate an additional 1.5 tonnes per annum of proprietary flower, including new strains, reinforcing its position as a leader in plant genetics and cultivation in the domestic market.

Advanced Manufacturing Capabilities: The expansion enables ANTG to commence Good Manufacturing Practice (GMP) of ethanol extractions for a range of products, including oils, vapes, pre-dosed flower, and pastilles (edibles).

Enhanced Export Capacity: Further boosts ANTG's capacity to export manufactured and plant-based products to the European Union and New Zealand, marking a critical step in global market expansion.

Job Creation: The expansion will create numerous jobs in Southeast Queensland, particularly in the areas of cultivation and novel manufacturing.

Outsourced Manufacturing Partnerships: Greater industry collaboration and best-practice services such as extraction, vape and oil filling and flower packing.

Executive General Manager, Pharmaceuticals, ANTG Andrew Cormack commented "The approval of our manufacturing permits enables us to extract resin, produce distillates, and manufacture oils, vaporisers, and pastilles.

We are looking forward to expanding our expertise and capability in this area by offering contract manufacturing services. I welcome the opportunity to discuss potential manufacturing partnerships to drive industry change and bring more capability onshore to provide Australian-grown and manufactured products to patients."

A Paradigm Shift in the Australian Market: The expansion coincides with the latest Global Prohibition Partners report, identifying Australia as an import-reliant market in the medicinal cannabis sector. ANTG's growth signifies a transformative shift towards a self-reliant, domestically driven market, showcasing the potential of Australian companies in this emerging field.¹

¹ <https://prohibitionpartners.com/reports/the-global-cannabis-report-4th-edition/>

A New Era for Australian Medicinal Cannabis: ANTG, an early pioneer in the sector, continues to lead the way in the Australian medicinal cannabis market. CEO Matt Cantelo says "With these latest developments, ANTG is not only poised to revolutionise the domestic market but also to make a significant impact on the global stage".

Welcoming Dirk Sprangers:

ANTG proudly announces the appointment of Dirk Sprangers as Technical Services Manager. Dirk, a veteran in greenhouse integration and project management from Europe and Australia, brings invaluable expertise in technical systems and innovative controlled environment agriculture.

Matt Cantelo, CEO of ANTG, said he was greatly enthused by Dirk's appointment, noting it as a direct result of the ODC permit approval. He praises Dirk's proficiency in system design, installation, and commissioning as crucial to ANTG's mission of delivering research-backed, quality-assured products.

"Dirk's passion for technology-driven agricultural practices and his commitment to producing high-quality crops efficiently and responsibly resonate deeply with ANTG's ethos".

"I am eager to contribute to ANTG's vision of pioneering in the field of plant-based medicines," Dirk Sprangers remarked. "My role at ANTG is not just a position, but a chance to make a real difference in the landscape of agricultural practices and medicinal cannabis."

While medicinal cannabis is not covered by the Pharmaceutical Benefits Scheme or Medicare, Australia continues to witness a significant increase in patient numbers and unapproved medicinal cannabis prescriptions, with annual patient numbers exceeding 110,000 in 2022.

For interview requests, contact:

Helen Kapalos 0426691703
Director of Communications and Community
Australian Natural Therapeutics Group
Helen.kapalos@australiannatural.com

About Australian Natural Therapeutics Group (ANTG)

Australian Natural Therapeutics Group delivers premium-grade, Australian-grown and manufactured quality-assured products. ANTG is at the forefront of providing effective solutions in healthcare, backed by a deep passion for the potential of plant-based medicine and cutting-edge technology.

Visit antg.com.au.